HC Wainwright Issues Pessimistic Estimate for INO Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Free Report) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.98) per share for the year, down from their prior estimate of ($0.73). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.11 EPS, Q4 2027 earnings at $0.20 EPS and FY2027 earnings at $0.18 EPS.

A number of other research firms have also recently issued reports on INO. Jefferies Financial Group restated a “buy” rating and issued a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Piper Sandler reissued an “overweight” rating and issued a $6.00 target price (down from $8.00) on shares of Inovio Pharmaceuticals in a research note on Wednesday, November 11th. Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a report on Wednesday, November 11th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.33.

Read Our Latest Report on Inovio Pharmaceuticals

Inovio Pharmaceuticals Price Performance

Shares of INO opened at $1.40 on Monday. The firm has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $1.27. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $2.27 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $2,780,000. Eversept Partners LP purchased a new position in Inovio Pharmaceuticals during the 1st quarter valued at about $1,802,000. LexAurum Advisors LLC purchased a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $118,000. Renaissance Technologies LLC boosted its stake in Inovio Pharmaceuticals by 16.4% during the first quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock worth $1,120,000 after acquiring an additional 90,613 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC boosted its stake in Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 53,510 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Featured Articles

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.